Raregen

Durham, United States Founded: 2018 • Age: 8 yrs Acquired By Liquidia
Strategy planning and investment consulting are provided for healthcare sectors.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products 3 Services tracked
Competitors 10 Brand Intelligence

About Raregen

Raregen is a company based in Durham (United States) founded in 2018 was acquired by Liquidia in June 2020. Raregen offers products and services including YUTREPIA, L606, and PRINT Technology. Raregen operates in a competitive market with competitors including Heartland Dental, AOK, Keplr Vision, The Chartis Group and Sterigenics, among others.

  • Headquarter Durham, United States
  • Sectors
    Financial Services
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Liquidia Corporation
Operational Areas
Financial Services → Banking & Financial Institutions Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    Liquidia

    (Jun 29, 2020)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Raregen

Raregen offers a comprehensive portfolio of products and services, including YUTREPIA, L606, and PRINT Technology.

Product name locked
Category locked
Primary

Inhaled treatment for pulmonary arterial hypertension.

Product name locked
Category locked
Locked

Drug candidate for pulmonary hypertension associated with lung disease.

Product name locked
Category locked
Locked

Proprietary system for enhancing drug efficacy in cardiopulmonary care.

People of Raregen

Headcount 10-50
Employee Profiles 45
Board Members and Advisors 7
Employee Profiles
People
Dana B.
Chief Accounting Officer
People
Yongzhi Dong
Sr Principal Scientist QC
People
Seth Hall
Senior Medical Science Liaison
People
Sean Y.
Senior Director, Commercial Ops & Analytics

Unlock access to complete

Funding Insights of Raregen

Premium access

Detailed funding history for Raregen

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Raregen

Raregen has secured backing from 1 investor. Prominent investors backing the company include Liquidia.

All
Investor Description Founded Year Domain Location
Engineered particles & films for life and material sciences applications
Locked Locked Locked
Premium access

Investor details for Raregen

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Raregen

Investments
Premium access

Investment portfolio details for Raregen

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Raregen

Premium access

Detailed financials for Raregen

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Raregen Comparisons

Raregen Primary company
Description
Strategy planning and investment consulting are provided for...
Location
Durham, United States
Founded Year
2018
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Raregen

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Raregen

Raregen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Heartland Dental, AOK, Keplr Vision, The Chartis Group and Sterigenics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Provider of healthcare consulting services
Locked Locked Locked
Medical insurance services for patients and employees are provided.
Locked Locked Locked
Business support and supply chain management services are offered.
Locked Locked Locked
Advisory services are offered to U.S. healthcare providers.
Locked Locked Locked
Provider of comprehensive sterilization solutions and expert consulting services
Locked Locked Locked
Contract manufacturing is provided for life sciences and diagnostics reagents.
Premium access

Detailed competitors of Raregen

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Raregen

Premium access

Complete news archive for Raregen

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Raregen

Raregen was founded in 2018.

Raregen is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.

Roger Jeffs is the current CEO of Raregen.

Raregen was founded in 2018 and is headquartered in Durham, United States. Consulting services focused on strategy planning and investment are offered to clients in the healthcare sector. Operations emphasize advisory support for sector-specific challenges, including market analysis and financial guidance. Leadership is provided by CEO Roger Jeffs, with expertise centered on healthcare innovation and growth strategies.

Raregen's top competitors include Qualicorp, Heartland Dental and Argonautms.

Raregen offers YUTREPIA, L606, and PRINT Technology.

Raregen has 1 investor. Key investors include Liquidia.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available